SAN DIEGO, CA--(Marketwire - January 26, 2011) - Cell Biolabs, Inc., a leader in life science products and research has introduced two new additions to its line of AAV Helper Free Systems: AAV-DJ and AAV-DJ/8. The first, AAV-DJ, was engineered via DNA family shuffling technology from 8 different native AAV serotypes to create a hybrid capsid. The resulting vector provides significantly higher in vitro infectivity rates across a broad range of cells and tissue types. AAV-DJ vectors have been shown to increase infectivity rates by up to 100,000-fold compared to heparin binding domain (HBD)-negative serotypes such as AAV-8 or AAV-9; even compared to other HBD-positive serotypes such as AAV-2, infectivity has been increased by up to 250-fold.
AAV-DJ/8 is a HBD-negative mutant of AAV-DJ. This HBD deletion allows superior uptake in brain and other tissues in vivo, similar to the transduction patterns of AAV-8 and AAV-9.
Packaging an infective recombinant adeno-associated virus (AAV) requires the presence of certain adenoviral gene products. The AAV Helper Free System eliminates the need for a helper adenovirus, making the system safer and more convenient.
These new additions, combined with the 2010 commercialization of AAV Helper Free Systems for serotypes AAV-1 through AAV-6, position Cell Biolabs as the clear commercial leader in providing AAV expression vector technology to the research community. Cell Biolabs now offers more than 50 different AAV Helper Free Expression and Packaging Systems.
About Cell Biolabs, Inc.
Cell Biolabs, Inc. proudly develops and commercializes innovative technologies and tools for life science research, with extensive experience in Cell-Based Assays, Viral Expression and Purification Reagents, Oxidative Stress Assays, and Small GTPase Kits and Reagents. The company is committed to providing the best products that facilitate discovery of the mechanisms underlying cell function and disease. For more information please contact krosser@cellbiolabs.com or visit www.cellbiolabs.com.
